Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Chronic bronchitis: when are antibiotics indicated?].

A U Gerber1

  • 1Medizinische Abteilung Regionalspital Burgdorf.

Therapeutische Umschau. Revue Therapeutique
|October 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Clinical thermometry--theory and critical approach].

Therapeutische Umschau. Revue therapeutique·2006
Same author

[Microbial resistance to antibiotics from the clinical viewpoint. Paradoxical therapy failures and the significance of pharmacokinetic-pharmacodynamic interactions in vivo].

Therapeutische Umschau. Revue therapeutique·2002
Same author

[A young man with sore throat and infection].

Schweizerische medizinische Wochenschrift·1997
Same author

Use of antimicrobials in Swiss hospitals. Swiss Committee of Anti-Infective Agents.

Drugs·1996
Same author

[Sources of error in the pre-analytical phase of blood gas analysis].

Praxis·1995
Same author

The impact of the pre-treatment interval on antimicrobial efficacy in a biological model.

The Journal of antimicrobial chemotherapy·1993
Same journal

[Multimodal Cardiac Imaging: New Developments for Clinical Practice].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Coronary angiography: From cardiac catheterization to advanced interventional cardiovascular imaging].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Athlete's heart: role of cardiac imaging in the prevention of sudden cardiac death].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Multimodal imaging in cardiac amyloidosis and cardiac sarcoidosis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

[Inflammatory Heart Disease: The Role of Multimodality Cardiac Imaging in Myocarditis and Pericarditis].

Therapeutische Umschau. Revue therapeutique·2026
Same journal

State-of-the-Art Cardiac Imaging

Therapeutische Umschau. Revue therapeutique·2026
See all related articles

Bacterial infections in chronic obstructive pulmonary disease (COPD) require careful antibiotic consideration. Antibiotic treatment for seven to ten days is recommended only for Anthonisen type-1 exacerbations, prioritizing safe and cost-effective oral options.

Area of Science:

  • Pulmonary Medicine
  • Infectious Diseases
  • Microbiology

Context:

  • Chronic obstructive pulmonary disease (COPD) exacerbations are often linked to bacterial infections.
  • The precise role of bacterial pathogens and the efficacy of antimicrobial chemotherapy in COPD management remain incompletely understood.
  • Current clinical guidelines offer limited direction on optimal antibiotic strategies for COPD patients.

Purpose:

  • To elucidate the significance of bacterial infections in the pathogenesis of COPD.
  • To define the appropriate role and duration of antimicrobial chemotherapy during COPD exacerbations.
  • To identify the most suitable oral antibiotic agents for treating bacterial infections in COPD patients.

Summary:

  • Bacterial infections play a complex role in COPD, with their impact on exacerbations still under investigation.

Related Experiment Videos

  • Antibiotic therapy, lasting seven to ten days, is advised specifically for Anthonisen type-1 exacerbations, characterized by increased sputum production and purulence.
  • For other COPD exacerbations, routine antibiotic use is not supported by current evidence.
  • The selection of antibiotics should prioritize agents with good tolerability, low toxicity, and cost-effectiveness, while demonstrating efficacy against common respiratory pathogens like Streptococcus pneumoniae and Haemophilus influenzae.
  • Aminopenicillins and cotrimoxazole are suggested as appropriate choices meeting these criteria.

    • Impact:

    • Provides evidence-based recommendations for targeted antibiotic use in COPD exacerbations.
    • Aims to optimize patient outcomes by preventing unnecessary antibiotic exposure and reducing the risk of antimicrobial resistance.
    • Guides clinicians in selecting appropriate, safe, and cost-effective antimicrobial agents for specific COPD patient populations.